259 related articles for article (PubMed ID: 21107284)
1. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
Tsao MS; Sakurada A; Ding K; Aviel-Ronen S; Ludkovski O; Liu N; Le Maître A; Gandara D; Johnson DH; Rigas JR; Seymour L; Shepherd FA
J Thorac Oncol; 2011 Jan; 6(1):139-47. PubMed ID: 21107284
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.
Ma X; Le Teuff G; Lacas B; Tsao MS; Graziano S; Pignon JP; Douillard JY; Le Chevalier T; Seymour L; Filipits M; Pirker R; Jänne PA; Shepherd FA; Brambilla E; Soria JC; Hainaut P;
J Thorac Oncol; 2016 Jun; 11(6):850-61. PubMed ID: 26899019
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer.
Zhu CQ; Ding K; Strumpf D; Weir BA; Meyerson M; Pennell N; Thomas RK; Naoki K; Ladd-Acosta C; Liu N; Pintilie M; Der S; Seymour L; Jurisica I; Shepherd FA; Tsao MS
J Clin Oncol; 2010 Oct; 28(29):4417-24. PubMed ID: 20823422
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.
Sun HB; Ou W; Li Y; Fang Q; Qin J; Zhang L; Wang SY
Clin Lung Cancer; 2013 Jul; 14(4):376-82. PubMed ID: 23291256
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T
J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
[TBL] [Abstract][Full Text] [Related]
7. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.
Yoshimasu T; Oura S; Ohta F; Hirai Y; Naito K; Nakamura R; Nishiguchi H; Hashimoto S; Kawago M; Okamura Y
J Thorac Oncol; 2011 Oct; 6(10):1658-62. PubMed ID: 21681119
[TBL] [Abstract][Full Text] [Related]
9. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
Shepherd FA; Domerg C; Hainaut P; Jänne PA; Pignon JP; Graziano S; Douillard JY; Brambilla E; Le Chevalier T; Seymour L; Bourredjem A; Le Teuff G; Pirker R; Filipits M; Rosell R; Kratzke R; Bandarchi B; Ma X; Capelletti M; Soria JC; Tsao MS
J Clin Oncol; 2013 Jun; 31(17):2173-81. PubMed ID: 23630215
[TBL] [Abstract][Full Text] [Related]
10. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Cappuzzo F; Ligorio C; Toschi L; Rossi E; Trisolini R; Paioli D; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Hirsch FR; Crino L; Varella-Garcia M
J Thorac Oncol; 2007 May; 2(5):423-9. PubMed ID: 17473658
[TBL] [Abstract][Full Text] [Related]
11. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Janjigian YY; Park BJ; Zakowski MF; Ladanyi M; Pao W; D'Angelo SP; Kris MG; Shen R; Zheng J; Azzoli CG
J Thorac Oncol; 2011 Mar; 6(3):569-75. PubMed ID: 21150674
[TBL] [Abstract][Full Text] [Related]
12. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T; Sakai K; Kenmotsu H; Yoh K; Daga H; Ohira T; Ueno T; Aoki T; Hayashi H; Yamazaki K; Hosomi Y; Chen-Yoshikawa TF; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Inokawa H; Yamamoto N; Nishio K; Tsuboi M
Cancer Sci; 2022 Jan; 113(1):287-296. PubMed ID: 34689382
[TBL] [Abstract][Full Text] [Related]
16. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
17. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Rulli E; Marabese M; Torri V; Farina G; Veronese S; Bettini A; Longo F; Moscetti L; Ganzinelli M; Lauricella C; Copreni E; Labianca R; Martelli O; Marsoni S; Broggini M; Garassino MC;
Ann Oncol; 2015 Oct; 26(10):2079-84. PubMed ID: 26209642
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Watanabe S; Minegishi Y; Yoshizawa H; Maemondo M; Inoue A; Sugawara S; Isobe H; Harada M; Ishii Y; Gemma A; Hagiwara K; Kobayashi K
J Thorac Oncol; 2014 Feb; 9(2):189-94. PubMed ID: 24419415
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
Leighl NB; Rizvi NA; de Lima LG; Arpornwirat W; Rudin CM; Chiappori AA; Ahn MJ; Chow LQ; Bazhenova L; Dechaphunkul A; Sunpaweravong P; Eaton K; Chen J; Medley S; Poondru S; Singh M; Steinberg J; Juergens RA; Gadgeel SM
Clin Lung Cancer; 2017 Jan; 18(1):34-42.e2. PubMed ID: 27686971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
